OncoMatch/Clinical Trials/NCT06860594
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
Is NCT06860594 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Triapine for astrocytoma, idh-mutant, grade 2.
Treatment: Triapine — This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has come back after a period of improvement (recurrent). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Giving triapine in combination with radiation therapy may be safe, tolerable, and/or effective in treating patients with recurrent glioblastoma or astrocytoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Glioblastoma
Diffuse Intrinsic Pontine Glioma
Biomarker criteria
Required: IDH1 mutation
Astrocytoma, IDH-mutant
Required: IDH2 mutation
Astrocytoma, IDH-mutant
Required: IDH1 wild-type
GBM or variants, IDH-wildtype
Required: IDH2 wild-type
GBM or variants, IDH-wildtype
Required: H3F3A (H3 K27M) G34 mutation
Diffuse midline gliomas, including pediatric-type H3 G34 mutant tumors
Required: HIST1H3B K27 mutation
Diffuse midline gliomas, including pediatric-type E3 K27 mutant tumors
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: radiation therapy — standard dose for gliomas (59.4-60 Gy in 1.8-2 Gy per fraction or equivalent or lower)
Prior history of standard dose radiation for gliomas of 59.4-60 gray (Gy) in 1.8-2 Gy per fraction (or equivalent or lower) is allowed
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1,500/mcL; Hemoglobin ≥ 8 g/dL; Platelets ≥ 100,000/mcL
Kidney function
Creatinine ≤ 1.5 x ULN OR glomerular filtration rate (GFR) ≥ 50 mL/min/1.73 m^2
Liver function
Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN); AST/ALT ≤ 3 x institutional ULN
Cardiac function
NYHA class II or better
Absolute neutrophil count ≥ 1,500/mcL. Hemoglobin ≥ 8 g/dL. Platelets ≥ 100,000/mcL. Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN). AST/ALT ≤ 3 x institutional ULN. Creatinine ≤ 1.5 x ULN OR GFR ≥ 50 mL/min/1.73 m^2. NYHA class II or better.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Comprehensive Cancer Center · Duarte, California
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care · Irvine, California
- UC San Diego Moores Cancer Center · La Jolla, California
- UC Irvine Health/Chao Family Comprehensive Cancer Center · Orange, California
- University of California Davis Comprehensive Cancer Center · Sacramento, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06860594 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received radiation therapy.
Does this trial require IDH1?
Yes, IDH1 mutation is a required biomarker for enrollment.
Does this trial require IDH2?
Yes, IDH2 mutation is a required biomarker for enrollment.
Does this trial require IDH1?
Yes, IDH1 wild-type is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify